Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza

References

• Nichol K, D’Heilly S, Greenberg M, Ehlinger E. Burden of influenza-like illness and effectiveness of influenza vaccination among working adults aged 50–64 years. Clin. Infect. Dis.48(3), 292–298 (2009).
   PubMed Web of Science ®Google Scholar
• Fleming D, Elliot A. The impact of influenza on the health and health care utilisation of elderly people. Vaccine23(Suppl. 1), S1–S9 (2005).
   PubMed Web of Science ®Google Scholar
• Thompson W, Shay D, Weintraub E et al. Influenza-associated hospitalizations in the United States. JAMA292(11), 1333–1340 (2004).
   PubMed Web of Science ®Google Scholar
• Takahashi M, Nagai M. Estimation of excess mortality associated with influenza epidemics specific for sex, age and cause of death in Japan during 1987–2005. Jpn. J. Hygiene63(1), 5–19 (2008).
   PubMedGoogle Scholar
• Morishima T, Togashi T, Yokita S et al. Encephalitis and encephalopathy with an influenza epidemic in Japan. Clin. Infect. Dis.35(5), 512–517 (2002).
   PubMed Web of Science ®Google Scholar
• Lackenby A, Hungnes O, Dudman SG et al. Emergence of resistance to oseltamivir among influenza A (H1N1) viruses in Europe. Eurosurveillance13, 1–2 (2008).
   Google Scholar
• Collins PJ, Haire LF, Lin YP et al. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature453, 1258–1261 (2008).
   PubMed Web of Science ®Google Scholar
• Katrina C, Chris S, Oliver K et al. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Lancet352(9144), 1877–1881 (1998).
   PubMedGoogle Scholar
• Mäkelä MJ, Pauksens K, Rostila T et al. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. J. Infect.40(1), 42–48 (2000).
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Hayden FG, Vrooman PS et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA283(8), 1016–1024 (2000).
   PubMed Web of Science ®Google Scholar
• Nicholson KG, Aoki FY, Osterhaus AD et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet355(9218), 1845–1850 (2000).
   PubMed Web of Science ®Google Scholar
• Kawai N, Ikematsu H, Iwaki N et al. Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002–2003 influenza season. Clin. Infect. Dis.40(9), 1309–1316 (2005).
   PubMed Web of Science ®Google Scholar
• Kawai N, Ikematsu H, Iwaki N et al. A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003–2004 and 2004–2005 influenza seasons. Clin. Infect. Dis.43(4), 439–444 (2006).
   PubMed Web of Science ®Google Scholar
• Kawai N, Ikematsu H, Hirotsu N et al. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese multicenter study of the 2007–2008 and 2008–2009 influenza seasons. Clin. Infect. Dis.49(12), 1828–1835 (2009).
   PubMed Web of Science ®Google Scholar
• Kawai N, Ikematsu H, Iwaki N et al. Clinical effectiveness of oseltamivir for influenza A(H1N1) virus with H274Y neuraminidase mutation. J. Infect.59(3), 207–212 (2009).
   PubMedGoogle Scholar
• Koyama K, Takahashi M, Oitate M et al. CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long retention profile in the mouse respiratory tract. Antimicrob. Agents Chemother.53(11), 4845–4851 (2009).
   PubMed Web of Science ®Google Scholar
• Kiso M, Kubo S, Ozawa M et al. Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses. PLoS Pathog.6(2), e1000786 (2010).
   PubMed Web of Science ®Google Scholar
• Yamashita M, Tomozawa T, Kakuta M et al. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob. Agents Chemother.53(1), 186–192 (2009).
   PubMed Web of Science ®Google Scholar
• Itoh Y, Shinya K, Kiso M et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature460(7258), 1021–1025 (2009).
   PubMed Web of Science ®Google Scholar
• Kubo S, Kakuta M, Yamashita M. In vitro and in vivo effects of a long-acting anti-influenza agent CS-8958 (laninamivir octanoate, Inavir) against pandemic (H1N1) 2009 influenza viruses. Jpn. J. Antibiot.63(5), 337–346 (2010).
   PubMedGoogle Scholar
• Yamashita M, Hirai T, Kubota K et al. Unique characteristics of long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) that explains its long lasting activity. Influenza Other Respi. Viruses5(Suppl. 1), 90–123 (2011).
   PubMedGoogle Scholar
• Ishizuka H, Yoshiba S, Okabe H et al. Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers. J. Clin. Pharmacol.50(11), 1319–1320 (2010).
   PubMed Web of Science ®Google Scholar
• Kubo S, Tomozawa T, Kakuta M et al. Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration. Antimicrob. Agents Chemother.54(3), 1256–1264 (2010).
   PubMed Web of Science ®Google Scholar
• Watanabe A, Chang SC, Kim MJ et al. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial. Clin. Infect. Dis.51(10), 1167–1175 (2010).
   PubMed Web of Science ®Google Scholar
• Sugaya N, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob. Agents Chemother.54(6), 2575–2582 (2010).
   PubMed Web of Science ®Google Scholar